Positive News Sentiment NASDAQ:TCRR TCR2 Therapeutics - TCRR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.48 +0.10 (+7.25%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.37▼$1.4850-Day Range$0.83▼$1.4852-Week Range$0.82▼$3.88Volume175,131 shsAverage Volume228,762 shsMarket Capitalization$57.22 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability TCR2 Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside626.4% Upside$10.75 Price TargetShort InterestHealthy3.50% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$83,594 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.18) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.98 out of 5 starsMedical Sector15th out of 1,049 stocksBiological Products, Except Diagnostic Industry4th out of 170 stocks 3.4 Analyst's Opinion Consensus RatingTCR2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.75, TCR2 Therapeutics has a forecasted upside of 626.4% from its current price of $1.48.Amount of Analyst CoverageTCR2 Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.50% of the float of TCR2 Therapeutics has been sold short.Short Interest Ratio / Days to CoverTCR2 Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TCR2 Therapeutics has recently decreased by 8.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTCR2 Therapeutics does not currently pay a dividend.Dividend GrowthTCR2 Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for TCR2 Therapeutics is -0.65. Previous Next 3.3 News and Social Media Coverage News SentimentTCR2 Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TCR2 Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for TCRR on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added TCR2 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TCR2 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,594.00 in company stock.Percentage Held by Insiders25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.76% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TCR2 Therapeutics are expected to grow in the coming year, from ($3.18) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TCR2 Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TCR2 Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTCR2 Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TCR2 Therapeutics (NASDAQ:TCRR) StockTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Read More Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Stock News HeadlinesJanuary 18, 2023 | reuters.comTCRR.C - | Stock Price & Latest News | ReutersJanuary 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)January 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 5, 2023 | finance.yahoo.comTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 5, 2023 | finance.yahoo.comTCR² Therapeutics Announces Pipeline Priorities for 2023January 2, 2023 | uk.finance.yahoo.comTCR2 Therapeutics Inc. (TCRR)December 16, 2022 | seekingalpha.comTCRR TCR2 Therapeutics Inc.November 23, 2022 | finance.yahoo.comTCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 11, 2022 | finance.yahoo.comDown 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)November 8, 2022 | finanznachrichten.deTCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | finance.yahoo.comTCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 7, 2022 | finance.yahoo.comTCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNovember 6, 2022 | finance.yahoo.comIs TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?September 28, 2022 | finance.yahoo.comTCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, MesotheliomaSeptember 28, 2022 | seekingalpha.comTCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trialSeptember 28, 2022 | finance.yahoo.comgavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and MesotheliomaSeptember 27, 2022 | finance.yahoo.comTCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsSeptember 26, 2022 | finance.yahoo.comTCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitAugust 19, 2022 | seekingalpha.comTCR² Therapeutics: Betting On A Solid ReversalAugust 8, 2022 | finance.yahoo.comTCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 8, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?August 8, 2022 | americanbankingnews.comTCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by BrokeragesJune 27, 2022 | marketwatch.comTCR2 Therapeutics Names Eric Sullivan Chief Financial Officer >TCRRJune 27, 2022 | finance.yahoo.comTCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial OfficerMay 30, 2022 | finance.yahoo.comWill TCR2 Therapeutics (NASDAQ:TCRR) Spend Its Cash Wisely?May 12, 2022 | finance.yahoo.comTCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Company Calendar Last Earnings11/08/2022Today1/29/2023Next Earnings (Estimated)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRR CUSIPN/A CIK1750019 Webwww.tcr2.com Phone(617) 949-5200FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.75 High Stock Price Forecast$18.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+626.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.52% Return on Assets-38.79% Debt Debt-to-Equity RatioN/A Current Ratio5.02 Quick Ratio5.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.36 per share Price / Book0.20Miscellaneous Outstanding Shares38,660,000Free Float28,989,000Market Cap$57.22 million OptionableNot Optionable Beta1.75 Key ExecutivesGarry E. MenzelPresident, Chief Executive Officer & DirectorPeter OlagunjuChief Operating OfficerEric M. SullivanChief Financial OfficerAlfonso Quintás-CardamaChief Medical OfficerPraveen MalhotraVice President-Information TechnologyKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLITradeUP AcquisitionNASDAQ:UPTDTalaris TherapeuticsNASDAQ:TALSSolid BiosciencesNASDAQ:SLDBIN8bioNASDAQ:INABView All CompetitorsInsiders & InstitutionsGarry E MenzelSold 10,613 sharesTotal: $11,674.30 ($1.10/share)Alfonso Quintas CardamaSold 4,586 sharesTotal: $5,044.60 ($1.10/share)Garry E MenzelSold 10,325 sharesTotal: $11,667.25 ($1.13/share)Alfonso Quintas CardamaSold 4,461 sharesTotal: $5,040.93 ($1.13/share)Garry E MenzelSold 9,111 sharesTotal: $11,662.08 ($1.28/share)View All Insider TransactionsView All Institutional Transactions TCRR Stock - Frequently Asked Questions Should I buy or sell TCR2 Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRR shares. View TCRR analyst ratings or view top-rated stocks. What is TCR2 Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued 1 year price targets for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $2.00 to $18.00. On average, they expect the company's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 626.4% from the stock's current price. View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts. How have TCRR shares performed in 2023? TCR2 Therapeutics' stock was trading at $0.9988 at the beginning of 2023. Since then, TCRR shares have increased by 48.2% and is now trading at $1.48. View the best growth stocks for 2023 here. When is TCR2 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our TCRR earnings forecast. How were TCR2 Therapeutics' earnings last quarter? TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.04. What other stocks do shareholders of TCR2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI). When did TCR2 Therapeutics IPO? (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. What is TCR2 Therapeutics' stock symbol? TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR." How do I buy shares of TCR2 Therapeutics? Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TCR2 Therapeutics' stock price today? One share of TCRR stock can currently be purchased for approximately $1.48. How much money does TCR2 Therapeutics make? TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $57.22 million. The company earns $-99,810,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis. How many employees does TCR2 Therapeutics have? The company employs 137 workers across the globe. How can I contact TCR2 Therapeutics? TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com. This page (NASDAQ:TCRR) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.